OPEN END TURBO BULL OPTIONSSCHEIN - VERTEX PHARMACEUTICALS | Real-time BOERSE MUENCHEN 15:40:17 2024-06-25 EDT | ||
| 17.62 EUR | -1.45% |
|
| Current month | +10.54% | ||
| 1 month | +9.31% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Latest news about VERTEX PHARMACEUTICALS INCORPORATED
More news
| Date | Price | Change |
|---|---|---|
| 24-06-25 | 17.62 | -1.45% |
| 24-06-24 | 17.88 | +2.64% |
| 24-06-21 | 17.42 | -0.63% |
| 24-06-20 | 17.53 | +2.51% |
| 24-06-19 | 17.1 | -0.70% |
Real-time BOERSE MUENCHEN
Last update June 25, 2024 at 03:40 pm
More quotesStatic data
| Product type | Knock-Out without Stop Loss |
|---|---|
| Buy / Sell | CALL |
| Underlying | VERTEX PHARMACEUTICALS INCORPORATED |
| Issuer | 
UniCredit
|
| WKN | HC3NX2 |
| ISIN | DE000HC3NX25 |
| Date issued | 2023-01-30 |
| Strike | 284.2 $ |
| Maturity | Unlimited |
| Parity | 10 : 1 |
| Emission price | 6.97 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 18.74 € |
|---|---|
| Lowest since issue | 3.43 € |
Company Profile
Vertex Pharmaceuticals Incorporated specializes in the research, development and marketing of micromolecular drugs primarily for the treatment of cancers, viral, inflammatory and auto-immune diseases.
Net sales are distributed geographically as follows: the United States (61.2%), Europe (31.5%) and other (7.3%).
Sector
-
Ratings for Vertex Pharmaceuticals Incorporated
Trading Rating
Investor Rating
ESG Refinitiv
B+
Consensus: Vertex Pharmaceuticals Incorporated
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
31
Last Close Price
473.8
USD
Average target price
465.5
USD
Spread / Average Target
-1.75%
- Stock Market
- Certificates
- Certificat
